Managing Drug Interactions

Introduction to Drug Interactions

Drug interactions can lead to serious adverse effects, including serotonin syndrome, QTc prolongation, and reduced therapeutic efficacy, and clinicians should identify high-risk combinations before prescribing multiple medications 1, 2
The cytochrome P450 enzyme system, particularly CYP3A4 and CYP2D6, is responsible for metabolizing numerous medications, and interactions can lead to serious adverse effects 1

Rifampin should generally not be coadministered with protease inhibitors (PIs), and rifabutin with dose adjustments should be used instead when a rifamycin is needed in patients on PI-based antiretroviral therapy, as recommended by the Centers for Disease Control and Prevention (CDC) 3, 4
Rifampin significantly reduces PI blood levels, potentially leading to treatment failure and development of resistance in patients with HIV 4
Rifampin should NOT be coadministered with most non-nucleoside reverse transcriptase inhibitors (NNRTIs) except efavirenz, as suggested by guidelines from the CDC and other organizations 3
Dose adjustments are required when using rifampin with most integrase strand transfer inhibitors (INSTIs), such as dolutegravir, which requires twice-daily dosing (50 mg BID) when coadministered with rifampin 3

If a patient is on a PI-based regimen, switch rifampin to rifabutin with appropriate dose adjustments, as recommended by the CDC and other health organizations 3, 4
Monitor HIV viral load more frequently (e.g., monthly initially) when starting rifampin with antiretrovirals, and check liver function tests regularly due to potential hepatotoxicity of both rifampin and many antiretrovirals 5
Do not discontinue antiretroviral therapy during acute TB treatment unless severe toxicity occurs, as advised by the CDC and other organizations 6
Never use rifabutin without dose adjustment when combining with PIs or NNRTIs, according to guidelines from the CDC and other health organizations 3

Baseline and regular monitoring of liver function tests, and regular assessment of HIV viral load and CD4 count are essential for patients on rifampin and antiretroviral therapy 5
Monitoring for drug-specific toxicities (e.g., visual changes with rifabutin) and adherence assessment for both TB and HIV medications are crucial for optimal patient outcomes 5

Elderly patients are at higher risk due to multiple medications and altered pharmacokinetics, and should be started with lower doses and titrated slowly when using potentially interacting medications 7
Cancer patients often receive multiple medications that interact through CYP450 pathways, and tyrosine kinase inhibitors are primarily metabolized by CYP3A4 and have significant interaction potential 8
Patients with HIV/TB coinfection require careful consideration of critical interactions, including rifampin significantly reducing levels of most protease inhibitors, and dose adjustments required when using rifabutin with ritonavir 9
Transplant recipients, such as those taking immunosuppressants (cyclosporine, tacrolimus), are CYP3A4 substrates with narrow therapeutic indices, and elderly patients may have reduced hepatic function, affecting drug metabolism and increasing sensitivity to interactions 10

The American Heart Association recommends that clinicians identify potential interactions, adjust dosages accordingly, and monitor for adverse effects to prevent serious complications when prescribing medications metabolized by CYP450 enzymes 11
The American College of Clinical Pharmacology recommends identifying high-risk patients, assessing the interaction, selecting an appropriate management strategy, and monitoring for effectiveness and toxicity to optimize medication efficacy while minimizing adverse effects 11
The Centers for Disease Control and Prevention recommends that clinicians consider critical interactions in HIV/TB coinfection, including rifampin significantly reducing levels of most protease inhibitors, and dose adjustments required when using rifabutin with ritonavir 9